We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

DYNEX

Designs and manufactures fully-automated ELISA microplate workstations, laboratory instruments and associated consuma... read more Featured Products: More products

Download Mobile App




Dynex Demonstrates Automated, High Throughput Agility ELISA System at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021

Dynex Technologies (Chantilly, VA, USA) demonstrated its automated, high throughput Agility ELISA system at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. More...

The event held at the Georgia World Congress Center in Atlanta, September 26-30 showcased the cutting-edge science and technology shaping the future of laboratory medicine.

Dynex is a leading designer and manufacturer of fully automated ELISA microplate workstations, laboratory instruments and associated consumables and accessories. From industry leading DSX and DS2 systems to the revolutionary Agility with SmartKit technology, Dynex is the leader in ELISA automation.

At AACC 2021, Dynex demonstrated its Agility fully integrated automated ELISA system that delivers high throughput with continuous plate loading flexibility for routine microplate testing. The fully automated platform allows users to optimize ELISA more than ever before, using electronic processing that provides premium precision with minimal manual operation. The technology relies on three precision robotic arms to accomplish the necessary tasks of sample pipetting, reagent pipetting and plates transporting.

The DYNEX AGILITY utilizes the proven versatility of ELISA’s core technology in a powerful, fully automated platform, for true ELISA optimization. Advanced robotic processing delivers unparalleled precision while eliminating nearly all manual steps, so AGILITY is efficient and reliable – freeing labs and their staff to be as productive as possible, while significantly reducing their cost per test.

Advanced robotics and direct-load reagent capability using innovative SmartKits provides operational efficiency. Agility Software offers sample serial dilution programming and run-time dilution capability ideal for COVID-19 Ab neutralization assays and other titer type assays. Automated onboard synchronization of sample dispense, and programmable wash cycles, help deliver high quality results. Quantitative or qualitative assays, with percentage inhibition calculations, can be fully automated with ease.

Related Links:
Dynex Technologies


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.